Research progress of hybrid coronary revascularization in treating coronary atherosclerotic heart disease
10.3969/j.issn.1006-5725.2025.06.022
- VernacularTitle:杂交冠状动脉血运重建技术治疗冠状动脉粥样硬化性心脏病研究进展
- Author:
Xiaoyu ZHANG
1
;
Yuanyuan PAN
;
Minghuan FU
;
Yun LIN
;
Yiran CHEN
;
Yu PENG
Author Information
1. 电子科技大学医学院(四川 成都 610054)
- Publication Type:Journal Article
- Keywords:
hybrid coronary revascularization;
coronary atherosclerotic heart disease;
percutaneous coronary intervention;
coronary artery bypass grafting;
progress
- From:
The Journal of Practical Medicine
2025;41(6):916-920
- CountryChina
- Language:Chinese
-
Abstract:
The incidence rate of coronary atherosclerotic heart disease(commonly referred to as coronary heart disease)remains high in China.In clinical practice,drug therapy,percutaneous coronary intervention(PCI),and coronary artery bypass grafting(CABG)are commonly employed.For patients with multi-vessel coronary artery stenosis,minimally invasive interventional therapy is often the preferred option.However,for those with multi-vessel disease complicated by comorbidities,CABG is generally recommended.Despite its advantages,PCI carries risks such as vascular restenosis,thrombosis,and other adverse events.Consequently,hybrid coronary revascularization(HCR)has emerged as an alternative approach.This paper provides an overview of coronary heart disease and re-views the advantages,applications,and patient selection criteria for HCR.
